Glukos Fresenius Kabi

Glukos Fresenius Kabi is a sterile solution for injection that contains glucose as the sole active ingredient. It is supplied in a parenteral form for intravenous administration and is marketed in the European Union. The product is classified as an excipient/solvent and is used under prescription for clinical situations requiring rapid glucose delivery and fluid replacement.

Glukos Fresenius Kabi is indicated for several clinical situations where rapid glucose supplementation and fluid balance are needed.

- Treatment of hypoglycemia in emergency or perioperative settings. - Fluid and electrolyte replacement for patients with dehydration or electrolyte disturbances. - Component of parenteral nutrition regimens to provide an energy source. - Support during surgical procedures to maintain blood glucose levels. - Management of metabolic disorders requiring controlled glucose infusion.

Side effects of intravenous glucose solutions are generally related to the osmolar load and rapid shifts in blood glucose.

Common: - Hyperglycemia when administered in excess. - Local irritation or pain at the infusion site. - Nausea or vomiting. - Headache. - Mild electrolyte imbalance (e.g., sodium, potassium).

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Fluid overload with pulmonary edema. - Hyperosmolar hyperglycemic state. - Allergic reaction or anaphylaxis to formulation components.

When using Glukos Fresenius Kabi, clinicians should consider several safety measures.

- Assess baseline blood glucose and electrolyte status before infusion. - Adjust infusion rate in patients with renal or cardiac insufficiency to avoid fluid overload. - Monitor for signs of hyperglycemia during and after administration. - Use caution in patients with known hypersensitivity to any component of the solution. - Ensure proper aseptic technique to prevent catheter-related infections. - Verify compatibility with other intravenous medications before co‑administration.

Glucose solutions can interact with other therapies, influencing efficacy or safety.

Avoid: - Co‑administration with high‑dose insulin without appropriate monitoring, which may precipitate severe hypoglycemia. - Simultaneous infusion of hypertonic solutions that could exacerbate hyperosmolar states.

Use with caution: - Concurrent use of diuretics, which may alter fluid and electrolyte balance. - Administration alongside potassium‑containing solutions; monitor serum potassium levels. - Use with catecholamines or glucocorticoids that can raise blood glucose. - Combination with other carbohydrate‑containing parenteral fluids; adjust total glucose load accordingly.